Latest News Feed
ASTCT® and CIBMTR® Bring Leading Experts Together to Share Groundbreaking Advancements in Hematopoietic Cell Transplantation, Cellular Therapy and Gene Therapy.
The Food and Drug Administration approves CAR T-Cell therapy Carvykti® as a second-line treatment and the CAR T-Cell therapy Abecma® as a third-line treatment for adult patients with multiple myeloma.
The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic stem cell transplantation (HSCT) for individuals with myelodysplastic syndromes (MDS) based on requests from ASH, ASTCT, NMDP, and CIBMTR.
The annual award honors Roberts’ special service to the patients and families that are served by the ASTCT community.
Global experts will share key insights to help healthcare professionals and researchers improve the lives of patients with blood-related disorders.
The Oct. 2-3 hybrid workshop will bridge the gap between critical stakeholders to pinpoint today's challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
